EGFR is an important factor in the RTK signaling pathway, and the IGF-1/2 neutralizing antibody m708.5 exhibits a strong synergistic effect with gefitinib, which shows benefit in the treatment of neuroblastoma and breast cancer (106). This evidence concerns the gene IGF1 and breast cancer.